IMMUTEP LIMITED - AMER

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

14 11 2024 07:15:00 提供 Nasdaq GlobeNewswire

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

14 11 2024 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q1 FY25

29 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

28 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

17 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

10 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

03 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

24 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

18 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

16 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

20 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

14 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Participate in Upcoming Investor Conferences

07 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q4 FY24

31 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

22 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

17 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

11 7 2024 17:40:40 提供 Nasdaq GlobeNewswire

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

03 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

25 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immutep successfully completes institutional placement and institutional component of entitlement offer

05 6 2024 05:00:00 提供 Nasdaq GlobeNewswire